Research Paper Volume 14, Issue 19 pp 7972—7985
DAZAP1 facilitates the alternative splicing of KITLG to promote multiple myeloma cell proliferation via ERK signaling pathway
Figure 1. Elevated DAZAP1 is associated with poor outcome of MM patients. (A) DAZAP1 expression in different stages of MM from the GSE5900 dataset as shown in the graph. The signal level of DAZAP1 (226620_at signaling) was shown on the y-axis. The groups of normal plasma (NP, n = 22), monoclonal gammopathy of undetermined significance (MGUS, n = 44), and multiple myeloma (MM, n = 351) were sorted on the x-axis, respectively. (B–F) Kaplan-Meier analysis of overall survival (OS) divided by high and low DAZAP1 expression in TT2, TT3, APEX, HOVON65 and GSE136337 cohorts. The number of patients in the cohorts was 351, 208, 264, 426 and 288, respectively. (G) DAZAP1 expression was increased in relapsed patient samples relative to the first diagnosis samples. (H) A box-plot showed DAZAP1 expression in eight MM subgroups.